Back to search

United Kingdom· GB-APID-4373111000001107

Hivid 750microgram tablets

A zalcitabine product containing zalcitabine, registered in United Kingdom by Roche Products Ltd. The same ATC class is registered in 2 of our 19 countries.

ATC J05AF03

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedHivid 750microgram tabletsATCJ05AF03REGISTER NO.GB-APID-4373111000001…PACKS LISTED0CHECKEDSeptember 13, 2026

Where it is registered

Zalcitabine is registered in 2 of 19 countries.

Countries holding a registration under ATC J05AF03 (zalcitabine), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 1 of them publish a price we can compare per daily dose

Zalcitabine · ATC J05AF03

2 / 19 countries

  • Finlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Zalcitabine
Manufacturer
Roche Products Ltd
Country
United Kingdom (GB)
ATC code
J05AF03
ATC class
Zalcitabine
Defined daily dose
2.25 mg, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

100 interactions on record for zalcitabine.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Zalcitabine · interactions on record

100 records

  • 7 severe
  • 84 moderate
  • 9 minor

Most severe, free to view

  • BexaroteneL01XF03severe
  • BexarotenL01XX25severe
  • LeflunomidL04AA13severe
  • TeriflunomidL04AA31severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Zalcitabine in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All zalcitabine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/90868097-1b92-43d8-90ac-bf39d152ee84
GET /v1/drugs/90868097-1b92-43d8-90ac-bf39d152ee84?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "4373111000001107",
  "desc": "Hivid 750microgram tablets (Roche Products Ltd)",
  "form": "Oral tablet",
  "vpid": "41796211000001106",
  "source": "dmd",
  "vtm_id": "777967002",
  "strength": "750 microgram",
  "substance": "Zalcitabine",
  "ingredient": "Zalcitabine",
  "supplier_code": "2085201000001100"
}

See everything about zalcitabine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.